美国儿童糖尿病管理市场规模、份额和趋势分析报告：按产品、技术、最终用途和细分市场预测，2025 年至 2033 年

市场规模和趋势

预计 2024 年美国儿童糖尿病管理市场规模为 20.159 亿美元，到 2033 年将达到 46.912 亿美元，2025 年至 2033 年的复合年增长率为 9.9%。

市场成长受多种因素驱动，包括儿童和青少年糖尿病盛行率的上升、糖尿病管理设备的技术进步，以及人们对早期诊断和主动糖尿病管理重要性的认识不断提高。此外，政府的支持和有利的监管倡议，包括旨在提高医疗保健可近性的倡议，也进一步推动了市场的成长。

美国儿童糖尿病的盛行率正在显着上升，这必然导致对糖尿病管理解决方案的需求增加。此外，向主动预防性医疗保健的转变，加上家长和医疗保健提供者认识的提高，正在推动早期诊断和早期疗育，从而进一步扩大市场。先进医疗保健基础设施的出现也推动了市场扩张，包括能够处理复杂糖尿病病例的专门小儿科诊所和医院。政府机构和私人组织更加重视病患教育和支持计划，这有助于改善疾病管理。例如，美国糖尿病协会 (ADA) 的「青少年力量计画」是一个免费的、以社区和学校为基础的项目，旨在帮助 5 至 12 岁的儿童降低 2 型糖尿病的风险并管理肥胖相关行为。该计划透过适合年龄的互动内容教育青少年健康饮食和规律体能活动的重要性。

此外，技术创新在推动儿童糖尿病管理市场成长方面发挥关键作用。先进胰岛素帮浦、连续血糖监测 (CGM) 系统和整合糖尿病管理平台的开发显着改善了儿童糖尿病管理。此外，一些市场参与企业正致力于开发能够自动化胰岛素输送的先进解决方案，进一步促进这些设备的普及。例如，2025 年 3 月，Tandem Diabetes Care 在美国推出了 Control-IQ+ 自动胰岛素输送技术，将其应用范围扩大到 2 岁及以上的 1 型糖尿病患者和 2 型糖尿病成人患者。 Control-IQ+ 与 t:slim X2 胰岛素帮浦和 Tandem Mobi 系统相容，具有扩展的体重和胰岛素参数、长达 8 小时的延长Bolus以及新的临时基础体温调节功能，可在运动、压力和疾病期间改善血糖管理。它还包含用于自动校正剂量的Bolus，旨在改善血糖控制、易用性和针对不同使用者的个人化服务。这些技术的不断发展，加上价格的不断下降和易用性的不断提高，预计将进一步推动市场扩张。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国儿童糖尿病管理市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 相关/辅助市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 美国儿童糖尿病管理市场分析工具
  • 产业分析—波特五力分析
  • PESTEL分析

第四章美国儿童糖尿病管理市场：产品、估计与趋势分析

• 细分仪表板
• 美国儿童糖尿病管理市场的产品差异分析
• 2021-2033 年美国儿童糖尿病管理市场规模及趋势分析（依产品）
• 血糖值监测仪（BGM）
• 连续血糖监测仪（CGM）
• 胰岛素帮浦
• 胰岛素笔
• 胰岛素注射器

第五章美国儿童糖尿病管理市场技术、预测与趋势分析

• 细分仪表板
• 美国儿童糖尿病管理市场技术变革分析
• 美国儿童糖尿病管理市场规模与趋势分析（依技术划分）（2021-2033）
• 连网型设备
• 未连网型设备

第六章美国儿童糖尿病管理市场最终用途、预测与趋势分析

• 细分仪表板
• 美国儿童糖尿病管理市场最终用途差异分析
• 美国儿童糖尿病管理市场规模及趋势分析（依最终用途），2021-2033 年
• 医院
  • 综合医院
  • 儿童医院
• 居家医疗
• 小儿科诊所

第七章 竞争态势

• 公司/竞争对手分类
• 战略地图
• 2024年企业市场分析
• 公司简介/上市公司
  • Medtronic
  • Dexcom
  • Abbott
  • Tandem Diabetes Care
  • Insulet Corporation
  • Novo Nordisk
  • Sanofi
  • Eli Lilly and Company
  • Roche Diabetes Care
  • Ascensia Diabetes Care

Market Size & Trends:

The U.S. pediatric diabetes management market size was estimated at USD 2,015.9 million in 2024 and is projected to reach USD 4,691.2 million in 2033, registering a CAGR of 9.9% from 2025 to 2033. The market growth is driven by several factors, including the rising prevalence of diabetes among children and adolescents, technological advancements in diabetes management devices, and the growing awareness of early diagnosis and the importance of proactive diabetes management. Additionally, government support and advantageous regulatory policies, such as efforts to enhance access to care, further drive market growth.

The U.S. is witnessing a significant rise in diabetes prevalence among children, necessitating a rise in demand for diabetes management solutions. Furthermore, the shift towards proactive and preventative healthcare, coupled with increased awareness among parents and healthcare providers, has fueled early diagnosis and intervention, further expanding the market. The market's expansion is also influenced by the availability of advanced healthcare infrastructure, including specialized pediatric clinics and hospitals equipped to handle complex diabetes cases. The growing emphasis on patient education and support programs, facilitated by both government and private organizations, contributes to improved disease management. For instance, the Project Power for Youth by the American Diabetes Association (ADA), a free, community- and school-based program, is designed to help children aged 5 to 12 reduce their risk of type 2 diabetes and manage obesity-related behaviors. The program educates youth on the importance of healthy eating and regular physical activity through interactive, age-appropriate content.

Moreover, technological innovation plays a crucial role in driving the growth of the pediatric diabetes management market. The development of advanced insulin pumps, CGM systems, and integrated diabetes management platforms has significantly improved pediatric diabetes management. Moreover, several market players are focusing on developing advanced solutions that can automate insulin delivery, which can further drive the adoption of these devices. For instance, in March 2025, Tandem Diabetes Care launched Control-IQ+ automated insulin delivery technology in the U.S., extending its use to people with type 1 diabetes aged 2 years and older, and adults with type 2 diabetes. Compatible with the t:slim X2 insulin pump and Tandem Mobi System, Control-IQ+ features expanded weight and insulin parameters, enhanced extended bolus up to 8 hours, and new temporary basal rate adjustments to better manage glucose during exercise, stress, or illness. It includes AutoBolus for automatic correction doses and aims to improve glucose control, ease of use, and personalization for diverse users. The continuous evolution of these technologies, coupled with their increasing affordability and ease of use, is further expected to drive market expansion.

U.S. Pediatric Diabetes Management Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pediatric diabetes management market report based on product, technology, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Blood Glucose Monitors (BGM)
• Continuous Glucose Monitors (CGM)
• Insulin Pumps
• Insulin Pens
• Insulin Syringes
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Connected Devices
• Non-connected Devices
• End Use Channels Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
  • General Hospitals
  • Children Hospitals
• Homecare
• Pediatric Clinics

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Technology Segment
  • 1.2.3. End use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. U.S. Pediatric Diabetes Management Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of diabetes in children
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Rising awareness about diabetes management
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of diabetes management devices
• 3.3. U.S. Pediatric Diabetes Management Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Pediatric Diabetes Management Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Pediatric Diabetes Management Market Product Movement Analysis
• 4.3. U.S. Pediatric Diabetes Management Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Blood Glucose Monitors (BGM)
  • 4.4.1. Blood Glucose Monitors (BGM) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Continuous Glucose Monitors (CGM)
  • 4.5.1. Continuous Glucose Monitors (CGM) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Insulin Pumps
  • 4.6.1. Insulin pumps market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Insulin Pens
  • 4.7.1. Insulin pens market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Insulin Syringes
  • 4.8.1. Insulin syringes market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Pediatric Diabetes Management Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Pediatric Diabetes Management Market Technology Movement Analysis
• 5.3. U.S. Pediatric Diabetes Management Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 5.4. Connected Devices
  • 5.4.1. Connected devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Non-connected Devices
  • 5.5.1. Non-connected devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Pediatric Diabetes Management Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Pediatric Diabetes Management Market End Use Movement Analysis
• 6.3. U.S. Pediatric Diabetes Management Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. General Hospitals
    • 6.4.2.1. General hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Children Hospitals
    • 6.4.3.1. Children hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Homecare
  • 6.5.1. Homecare market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Pediatric Clinics
  • 6.6.1. Pediatric clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Company Profiles/Listing
  • 7.4.1. Medtronic
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Dexcom
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Abbott
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Tandem Diabetes Care
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Insulet Corporation
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Novo Nordisk
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Sanofi
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Eli Lilly and Company
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Roche Diabetes Care
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Ascensia Diabetes Care
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. pediatric diabetes management market by product, 2021 - 2033 (USD Million)
• Table 4 U.S. pediatric diabetes management market by technology 2021 - 2033 (USD Million)
• Table 5 U.S pediatric diabetes management market by End Use, 2021 - 2033 (USD Million)
• Table 6 Participant's overview
• Table 7 Financial performance
• Table 8 Key companies undergoing expansions
• Table 9 Key companies undergoing acquisitions
• Table 10 Key companies undergoing collaborations
• Table 11 Key companies launching new products
• Table 12 Key companies undergoing partnerships
• Table 13 Key companies undertaking other strategies

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Market formulation & validation
• Fig. 4 U.S. pediatric diabetes management market: Market outlook
• Fig. 5 U.S. pediatric diabetes management market: Segment outlook
• Fig. 6 U.S. pediatric diabetes management market: Competitive landscape outlook
• Fig. 7 Parent market outlook
• Fig. 8 U.S. pediatric diabetes management market driver impact
• Fig. 9 U.S. pediatric diabetes management market restraint impact
• Fig. 10 U.S. pediatric diabetes management market, product outlook key takeaways (USD Million)
• Fig. 11 U.S. pediatric diabetes management market product movement analysis 2024 & 2033 (USD Million)
• Fig. 12 Blood glucose monitors market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 13 Continuous glucose monitors market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 14 Insulin pumps market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 15 Insulin pens market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 16 Insulin syringes market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 17 U.S. pediatric diabetes management market, technology outlook key takeaways (USD Million)
• Fig. 18 U.S. pediatric diabetes management market technology movement analysis 2024 & 2033 (USD Million)
• Fig. 19 Connected devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 20 Non-connected devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 21 U.S. pediatric diabetes management market, End Use outlook key takeaways (USD Million)
• Fig. 22 U.S. pediatric diabetes management market End Use movement analysis 2024 & 2033 (USD Million)
• Fig. 23 Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 24 General hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 25 Children hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 26 Homecare market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 27 Pediatric clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 28 Heat map analysis
• Fig. 29 Market participant categorization
• Fig. 30 U.S. pediatric diabetes management market share analysis, 2024
• Fig. 31 Strategy framework